News Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 by trophic 10 September, 2022
News Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME by trophic 23 August, 2022
News Immatics Announces Second Quarter 2022 Financial Results and Business Update by trophic 09 August, 2022
